Medindia

X

NxStage® Awarded Contract to Supply Atlantic Dialysis Management Services with Streamline® Blood Tubing Sets

Wednesday, June 23, 2010 General News J E 4
Advertisement


LAWRENCE, Mass., June 23 NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that its Medisystems division has been awarded an exclusive five-year blood tubing supply contract with Atlantic Dialysis Management Services. Under the terms of the agreement, Atlantic Dialysis will now use Medisystems' Streamline® airless blood tubing set in all of its facilities.

"With high value products like Streamline, Medisystems is helping customers achieve both their clinical objectives and operational goals," said Mark Florence, Vice President & General Manager, Medisystems. "We are pleased that Atlantic Dialysis has chosen Streamline, and believe this win further validates the clinical and operational superiority of Streamline versus traditional bloodlines."

"We are extremely pleased to have chosen Streamline and believe that the relationship will provide continued clinical improvement and significant operational savings," said J. Ganesh Bhat, M.D., Co-Principal, Atlantic Dialysis Management Services, L.L.C. "With the implementation and impact of the CMS Bundled Payment in 2011, it is essential to be partnered with a well established company that can lend support and assistance to help our affiliates succeed."

Medisystems' latest generation blood tubing set is the Streamline®, which features an efficient and airless design intended to improve clinical and economic performance. Streamline is designed to reduce dialysate flow, dialyzer size, treatment time, minimize heparin and waste, and optimize dose delivery, as measured in Kt/V. Streamline also includes Medisystems' patented LockSite® needleless access ports, which eliminate the need for sharp needles or costlier guarded needles to be used with the tubing set during dialysis.

About NxStage Medical

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products, please visit the company's website at http://www.nxstage.com.

About Atlantic Dialysis Management Services, L.L.C.

Atlantic Dialysis Management Services, L.L.C. was established to provide new dialysis site development, day to day administration and management of dialysis services and related business development activities. The business strategy is to maximize individual site results through consolidated activities. Central to the ADMS approach is the long term control of these clinical services by nephrologists. Atlantic Dialysis Affiliates will provide over 160,000 dialysis treatments in 2009 to an estimated 1,500 patients in New York City and Long Island.

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including, but not limited to, changes relating to customer demand for NxStage's blood tubing sets and other products and other factors that are discussed in NxStage's filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2010. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Contact: Kristen K. Sheppard, Esq. Investor Relations ksheppard@nxstage.com

SOURCE NxStage Medical, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
First Time Convergent Procedure Study Reports One-...
S
Satisfied With Stelara's Efficacy and Dosing, Near...